Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Monte Rosa Therapeutics (GLUE) Revenue (2024 - 2025)

Monte Rosa Therapeutics (GLUE) has 2 years of Revenue data on record, last reported at $12.8 million in Q3 2025.

  • For Q3 2025, Revenue rose 38.54% year-over-year to $12.8 million; the TTM value through Sep 2025 reached $181.5 million, up 1112.27%, while the annual FY2024 figure was $75.6 million, N/A changed from the prior year.
  • Revenue reached $12.8 million in Q3 2025 per GLUE's latest filing, down from $23.2 million in the prior quarter.
  • Across five years, Revenue topped out at $84.9 million in Q1 2025 and bottomed at $1.1 million in Q1 2024.